Sector News

For sale: Bankrupt Dendreon and its laggard Provenge, for $275M or more. Any takers?

November 10, 2014
Life sciences
Struggling Dendreon has tried streamlining its manufacturing process for cancer vaccine Provenge. It’s tried laying off hundreds of employees, cutting operating costs and raising capital. And it’s tried putting itself up for sale. But no dice: The company is still swimming in a sea of debt that Monday spurred it to file for Chapter 11 bankruptcy protection.
 
Dendreon’s prepackaged bankruptcy includes another attempt to sell itself, via an auction with qualifying bids starting at $275 million–a far cry from the price it hoped to get back when Provenge was expected to soar to blockbuster sales.
 
It also has struck a deal with note holders to convert their debt into shares. The Washington-based biotech owes $620 million in convertible debt due in 2016. In the meantime, Dendreon intends to continue operations, and it’ll continue providing Provenge to patients, it said.
 
Analysts expected big things from the Seattle company when Provenge became the first cancer vaccine to win FDA approval. But multiple hurdles–including a hefty $93,000 price tag and stellar launches from new, more convenient rivals Xtandi from Astellas and Medivation, and Zytiga from Johnson & Johnson ($JNJ)–prevented the treatment from living up to its potential: Analysts have revised their 2020 annual sales estimates from $4.3 billion to $378 million, Bloomberg notes.
 
Now, “the company has concluded that even if it was able to successfully realize its current operating projections, it would likely be unable to repay or refinance the 2016 notes when they mature and, as such, the business would not be viable on a standalone basis absent a strategic transaction or restructuring of its debt,” its 8-K says.
 
Dendreon has tried the whole “sell itself” thing before. Last year, it enlisted JPMorgan and Merrill Lynch to conduct a “broad confidential auction process,” but no suitors emerged. And this spring, the company “discussed the possibility of a combination with two separate third parties,” but talks didn’t advance beyond the early stages, it said in a court filing.
 
This time, Lazard got a head start on its behalf, reaching out to 40 potential buyers beginning this September. Part of the goal was to afford potential buyers “time to evaluate the opportunity in advance of any in-court sale process,” Dendreon said.
 
By Carly Helfand
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]